Novel crystal form of ellastriate hydrochloride and its preparation method
By preparing and characterizing new polymorphs of ellastrone hydrochloride, namely M, S, N, ellastrone succinate, and ellastrone fumarate, the problem of insufficient research on polymorphisms of ellastrone hydrochloride was solved, the performance characteristics of drug compositions were improved, and the needs of drug dosage form design were met.
Patent Information
- Application Number
- CN202580026122.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-10-30
- Filing Date
- 2025-03-29
- Publication Date
- 2026-11-10
AI Technical Summary
Existing technologies have failed to fully study and develop the polymorphic forms of ellastrone hydrochloride, affecting its performance characteristics such as solubility, stability, flowability, and processability in pharmaceutical compositions.
Novel crystal forms of ellasyl hydrochloride, including M, S, N, ellasyl succinate, and ellasyl fumarate, were developed. They were prepared and micronized using different solvents and methods, and characterized by X-ray diffraction.
It provides irilast hydrochloride crystal forms with different physical properties, improving the solubility, stability and flowability of finished drugs, broadening the choices for formulation scientists when designing drug dosage forms, and meeting the requirements of drug compositions.
Smart Images

Figure CN123076583A_ABST
Abstract
Description
Related applications
[0001] This application claims priority to the following Indian patent applications: No. 202441026692, filed on March 30, 2024; No. 202441047877, filed on June 21, 2024; and No. 202441083435, filed on October 30, 2024, the disclosures of which are incorporated herein by reference in their entirety. Technical Field
[0002] This invention relates to a novel crystal form of allaspirin hydrochloride represented by the following formula -1a and its preparation method.
[0003]
[0004] The present invention also relates to a new salt of the alas group of formula-1 represented by the following formula and a method for preparing the same.
[0005] . Background Technology
[0006] The chemical name of ellastrant hydrochloride is (6R)-6-(2-(N-(4-(2-(ethylamino)ethyl)benzyl)-N-ethylamino)-4-methoxyphenyl)-5,6,7,8-tetrahydronaphthyl-2-ol dihydrochloride, i.e., compound -1a. It is approved in the United States under the brand name ORSERDU(tm) for the treatment of postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutant advanced or metastatic breast cancer who have experienced disease progression after at least one line of endocrine therapy.
[0007] US Patent 7,612,114B2 describes a method for preparing ellastatin hydrochloride. US Patent 10,385,008B2 describes ellastatin hydrochloride in crystal form 1, crystal form 2, crystal form 3, and a mixture of crystal form 2 and crystal form 3. US Patent 11,643,385B2 describes ellastatin hydrochloride in crystal form 1B.
[0008] WO2022056100A1 describes the eutectic of ellastan hydrochloride and urea (crystal form A); ellastan free base (crystal form B1); ellastan monohydrochloride (crystal form H1); crystalline ellastan hydrochloride crystal form 6 (DMSO solvate); crystalline ellastan hydrochloride crystal form 7 (1-propanol solvate); and crystalline ellastan hydrochloride crystal form 9.
[0009] WO2023227029A1 describes the crystalline form of lassyl hydrochloride (CSII).
[0010] WO2024104268A1 describes the cocrystals of ellasyl hydrochloride and succinic acid (CSIV), ellasyl hydrochloride and tartaric acid (CSV), and ellasyl hydrochloride and malic acid (CSVI).
[0011] Polymorphism refers to the phenomenon that a single compound can exhibit different crystal forms; it is a property possessed by certain compounds and coordination compounds. Therefore, polymorphs are different solids with the same molecular formula, and each polymorph can have different physical properties.
[0012] Therefore, a single compound can produce multiple polymorphs, each with different and unique physical properties, such as different solubility characteristics, different melting point temperatures, and / or different X-ray diffraction peaks. Since the solubility of each polymorph can vary, identifying the presence of drug polymorphs is crucial for providing drugs with predictable solubility properties. It is desirable to investigate all solid-state forms of drugs (including all polymorphs) and determine the stability, dissolution, and flow properties of each polymorph.
[0013] Polymorphic forms of compounds can be distinguished in the laboratory using X-ray diffraction spectroscopy and other methods such as infrared spectroscopy. Furthermore, polymorphic forms of the same active pharmaceutical ingredient or active pharmaceutical ingredient can be administered alone or formulated into a drug product (also known as the final dosage form or finished product). It is well known that polymorphic forms can affect, for example, the solubility, stability, flowability, processability, and compressibility of the active pharmaceutical ingredient.
[0014] Therefore, there is still a need to develop other solid forms or polymorphs of ellastrone hydrochloride to meet pharmaceutical requirements.
[0015] Because developing new polymorphic forms of active pharmaceutical ingredients can provide new opportunities to improve the performance characteristics of finished drug products, the development of new polymorphic forms is always encouraged.
[0016] In addition, solid-state studies of active pharmaceutical ingredients aim to broaden the range of polymorphs available to formulation scientists when designing drug dosage forms with desired characteristics.
[0017] Through extensive efforts, the inventors unexpectedly discovered the crystal form of ellastrone hydrochloride and a new salt of ellastrone, which can be used to prepare various pharmaceutical compositions. Summary of the Invention
[0018] The first embodiment of the present invention provides a new crystal form of the allasu group of formula -1a, hereinafter referred to as crystal form M.
[0019] The second embodiment of the present invention provides a method for preparing crystal form M of the allaspirin group of formula -1a.
[0020] The third embodiment of the present invention provides a new crystal form of the allasu group of formula-1a, hereinafter referred to as crystal form S.
[0021] The fourth embodiment of the present invention provides a method for preparing crystal form S of the allaspirin group of formula -1a.
[0022] The fifth embodiment of the present invention provides a method for micronizing the crystal form S of the allaspirin group of formula 1a.
[0023] The sixth embodiment of the present invention provides a variable humidity powder X-ray diffraction (VH-PXRD) study of the crystal form S of the allasyl hydrochloride group of formula -1a.
[0024] The seventh embodiment of the present invention provides a variable humidity powder X-ray diffraction (VH-PXRD) study of the micronized crystal form S of the allasu group of formula -1a.
[0025] The eighth embodiment of the present invention provides a powder X-ray diffraction (PXRD) study of crystal form S of the allasu group of formula-1a, which was conducted and collected under closed conditions in a desiccator at 0% relative humidity (%RH).
[0026] The ninth embodiment of the present invention provides a powder X-ray diffraction (PXRD) study of the micronized crystal form S of the allasu group of formula -1a, which was conducted and collected under closed conditions in a desiccator at 0% RH.
[0027] The tenth embodiment of the present invention provides a variable temperature powder X-ray diffraction (VT-PXRD) study of the crystal form S of the allasyl hydrochloride group of formula -1a.
[0028] The eleventh embodiment of the present invention provides a variable temperature powder X-ray diffraction (VT-PXRD) study of the micronized crystal form S of the allasu group of formula -1a.
[0029] The twelfth embodiment of the present invention provides a method for preparing crystal form 1B of the allaspirin group of formula -1a.
[0030] The thirteenth embodiment of the present invention provides a new crystal form of the allasu group of formula-1a, hereinafter referred to as crystal form N.
[0031] The fourteenth embodiment of the present invention provides a method for preparing the crystal form N of the allaspirin group of formula -1a.
[0032] The fifteenth embodiment of the present invention provides lassyl succinate of formula-1b.
[0033] The sixteenth embodiment of the present invention provides a method for preparing lassyl succinate of formula -1b.
[0034] The seventeenth embodiment of the present invention provides ellaxis group of formula -1c fumarate.
[0035] The eighteenth embodiment of the present invention provides a method for preparing ellastrone fumarate of formula -1c. Attached Figure Description
[0036] Figure 1 The powder X-ray diffraction (PXRD) pattern of crystal form M of the allasu group hydrochloride is shown.
[0037] Figure 2 The PXRD pattern of crystal form S of the allasu group hydrochloride obtained according to Example 2 is shown.
[0038] Figure 3 The PXRD pattern of crystal form S of the allasu group hydrochloride obtained according to Example 3 is shown.
[0039] Figure 4 The PXRD pattern of micronized crystal form S of the allasu group hydrochloride obtained according to Example 4 is shown.
[0040] Figure 5 The image shows a superimposed diagram of the VH-PXRD spectra of crystal form S collected under different %RH conditions.
[0041] Figure 6 The image shows a superimposed diagram of the VT-PXRD patterns of crystal form S collected at different temperatures.
[0042] Figure 7 The image shows a superimposed VH-PXRD pattern of micronized crystal form S collected under different %RH conditions.
[0043] Figure 8 The image shows a superimposed diagram of the VT-PXRD patterns of micronized crystal form S collected at different temperatures.
[0044] Figure 9 The image shows the PXRD pattern of crystal form S after exposure to 0%RH for 2 hours.
[0045] Figure 10 The PXRD pattern of micronized crystal form S after exposure to 0%RH for 2 hours is shown.
[0046] Figure 11 PXRD patterns of crystal form 1B of the allasu group obtained according to Examples 5 and 6 are shown.
[0047] Figure 12The PXRD pattern of the N crystal form of the allasu group hydrochloride is shown.
[0048] Figure 13 The PXRD pattern of crystal form M of the succinate lassyl group is shown.
[0049] Figure 14 The PXRD pattern of crystal form S of the elasis group of fumarate is shown. Detailed Implementation
[0050] The term "solvent" as used herein refers to: "hydrocarbon solvents," such as n-hexane, n-heptane, cyclohexane, petroleum ether, benzene, toluene, pentane, cycloheptane, methylcyclohexane, ethylbenzene, m-, o-, or p-xylene, or naphthalene, etc.; "ether solvents," such as dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, methyl tert-butyl ether, diisopropyl ether, 1,2-dimethoxyethane, etc.; "ester solvents," such as methyl acetate, ethyl acetate, isopropyl acetate, n-butyl acetate, etc.; and "polar aprotic solvents," such as dimethylacetamide (DMA), N,N-dimethylformamide (D... MF), diethylene glycol dimethyl ether, dimethyl sulfoxide (DMSO), N-methylpyrrolidone (NMP), etc.; "chlorinated solvents", such as dichloromethane, dichloroethane, chloroform, carbon tetrachloride, etc.; "ketone solvents", such as acetone, methyl ethyl ketone, methyl isobutyl ketone, etc.; "nitrile solvents", such as acetonitrile, propionitrile, isobutyronitrile, etc.; "alcohol solvents", such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol, tert-butanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, propylene glycol, 2-methoxyethanol, 2-ethoxyethanol, diethylene glycol, 1-, 2- or 3-pentanol, neopentanol, tert-pentanol, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol or glycerol, etc.; "polar solvents", such as water, or mixtures thereof.
[0051] As used herein, the term "pharmaceutically acceptable salt" or "salt" includes, but is not limited to: hydrohalides, such as hydrochlorides, hydrobroms, and hydroiodides; inorganic acid salts, such as nitrates, perchlorates, sulfates, or phosphates; lower alkyl sulfonates, such as methanesulfonates or ethanesulfonates; aryl sulfonates, such as benzenesulfonates or p-toluenesulfonates; organic acid salts, such as acetates, malates, fumarates, succinates, citrates, ascorbic acid salts, tartrates, oxalates, or maleates; or amino acid salts, such as glycine salts, lysine salts, arginine salts, ornithine salts, glutamate salts, aspartate salts; salicylates, 1,5-naphthalenedisulfonates, etc.
[0052] The first embodiment of the present invention provides a new crystal form of the allaspirin group compound of formula -1a, hereinafter referred to as crystal form M.
[0053] In a first aspect of the first embodiment, a crystal form M of ellasyl hydrochloride is provided, characterized by its PXRD pattern as follows: Figure 1 As shown.
[0054] A second embodiment of the present invention provides a method for preparing crystal form M of the elasis hydrochloride group of formula -1a, comprising: a) Provide a solution of ellastatin hydrochloride in N,N-dimethylformamide (DMF). b) Crystal form M of the isolax hydrochloride group of the isolated form -1a; The solution provided in step a) can be prepared by dissolving ellastan hydrochloride in N,N-dimethylformamide at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used, or the solution in step a) can be obtained by a synthetic process for preparing ellastan hydrochloride; the separation of the crystal form M of ellastan hydrochloride in step b) can be performed by mixing with an antisolvent and then filtering the compound; wherein the antisolvent is methyl tert-butyl ether.
[0055] The third embodiment of the present invention provides a new crystal form of the allasu group of formula-1a, hereinafter referred to as crystal form S.
[0056] The first aspect of the third embodiment provides a crystal form S of the allasu group of formula-1a, characterized in that its powder X-ray diffraction (PXRD) pattern has peaks at approximately 3.0°, 6.1°, 9.6° and 24.1° ± 0.2° 2θ.
[0057] A second aspect of the third embodiment provides a crystal form S of the allasu group of formula-1a, characterized in that its powder X-ray diffraction (PXRD) pattern has peaks at approximately 7.9° and 11.9° ± 0.2° 2θ.
[0058] A third aspect of the third embodiment provides a crystal form S of the allasu group of formula-1a, characterized in that its powder X-ray diffraction (PXRD) peaks are located at about 7.9°, 9.6° and 11.9° ± 0.2° 2θ.
[0059] A fourth aspect of the third embodiment provides a crystal form S of the allaspirin group of formula-1a, characterized in that its powder X-ray diffraction (PXRD) pattern has peaks at approximately 7.9°, 9.6°, and 11.9° ± 0.2° 2θ, said pattern as follows: Figure 2 As shown.
[0060] The fifth aspect of the third embodiment provides a crystal form S of the allasu group of formula-1a, characterized in that its powder X-ray diffraction (PXRD) peaks are located at about 7.9°, 9.6° and 11.9° ± 0.2° 2θ, and also have peaks at about 3.0°, 6.1° and 24.1° ± 0.2° 2θ.
[0061] The sixth aspect of the third embodiment provides a crystal form S of the allasu group of formula-1a, characterized in that its powder X-ray diffraction (PXRD) peaks are located at about 3.0°, 6.1°, 7.9°, 9.6°, 11.9° and 24.1° ± 0.2° 2θ.
[0062] The seventh aspect of the third embodiment provides a crystal form S of ellasyl hydrochloride, characterized in that its PXRD pattern is substantially as follows: Figure 2 As shown.
[0063] The eighth aspect of the third embodiment provides a crystal form S of ellasyl hydrochloride, characterized in that its PXRD pattern is substantially as follows: Figure 3 and Figure 4 As shown.
[0064] In the ninth aspect of the third embodiment, the crystal form S of the allaspirin hydrochloride is stable.
[0065] The fourth embodiment of the present invention provides a method for preparing crystal form S of the elasis group of formula -1a, comprising: a) Dissolve or suspend leprastran hydrochloride in a solvent. b) Crystal form S of the isolax hydrochloride group of the isolated form -1a.
[0066] In a first aspect of the fourth embodiment, the dissolution or suspension of ellastatin hydrochloride in step a) can be carried out by mixing the ellastatin hydrochloride in a solvent at a suitable temperature in the range of about 0°C to the reflux temperature of the solvent, or it can be obtained by a synthetic process for preparing ellastatin hydrochloride.
[0067] In a second aspect of the fourth embodiment, the solvent in step a) is selected from ketone solvents, alcohol solvents, ester solvents, ethyl formate, water, and / or mixtures thereof.
[0068] In a third aspect of the fourth embodiment, the solvent is a mixture of a ketone solvent and water.
[0069] In a fourth aspect of the fourth embodiment, the ketone solvent is acetone.
[0070] In a fifth aspect of the fourth embodiment, separating the crystal form S of the ellasyl hydrochloride in step b) involves removing the solvent by a suitable technique, including but not limited to decantation, evaporation, flash evaporation, concentration of the mixture, stirred film drying (ATFD), melt extrusion, spray drying, freeze drying (lyophilization), spray freeze drying, cooling the mixture or solution to a lower temperature and then filtering, film drying, mixing with an antisolvent, or any other suitable technique known in the art.
[0071] In a sixth aspect of the fourth embodiment, the separation of the crystal form S in step b) can be carried out by evaporation and concentration of the mixture.
[0072] In a seventh aspect of the fourth embodiment, the separation of the crystal form S in step b) can be performed by cooling the mixture obtained in step a) to a lower temperature and then filtering it.
[0073] In an eighth aspect of the fourth embodiment, prior to separating the crystal form S, a second solvent is optionally added to the mixture obtained in step a), wherein the second solvent is selected from ketone solvents.
[0074] In the ninth aspect of the fourth embodiment, the separation of the crystal form S in step b) can be carried out by mixing with an antisolvent, wherein the antisolvent is selected from ketone solvents and ester solvents.
[0075] In the tenth aspect of the fourth embodiment, the antisolvent is acetone.
[0076] In the eleventh aspect of the fourth embodiment of the present invention, a method for preparing crystal form S of the elasis group of formula -1a is provided, comprising: a) Provide a solution of ellastatin hydrochloride in a mixture of acetone and water. b) Crystal form S of the isolaxyl hydrochloride group of the isolated form -1a; The solution provided in step a) can be prepared by dissolving ellastatin hydrochloride in a mixture of acetone and water at a suitable temperature in the range of about 25°C to the reflux temperature of the solvent, or the solution in step a) can also be obtained by a synthetic process for preparing ellastatin hydrochloride; the separation of ellastatin hydrochloride crystal form S in step b) can be carried out by removing the solvent from the solution by antisolvent crystallization, cooling crystallization, precipitation, evaporation crystallization, distillation, or optionally concentration under reduced pressure.
[0077] The fifth embodiment of the present invention provides a method for micronizing the crystal form S of the allaspirin group of formula 1a.
[0078] In the first aspect of the fifth embodiment, the micronization of crystal form S is carried out by pulverizing (and / or re-pulverizing) using an air jet milling process, with a feed rate of 1 to 5 kg / cm².2 The crushing pressure is 2.0 to 7.0 kg / cm². 2 .
[0079] In the second aspect of the fifth embodiment, the PXRD pattern of the micronized crystal form S of ellastatin hydrochloride is as follows: Figure 4 As shown.
[0080] In a third aspect of the fifth embodiment of the present invention, the crystal form S of the elasis hydrochloride of formula -1a produced by the present invention is characterized by its particle size distribution: wherein 90% of the particles have a particle size (D90) of less than about 100 μm, preferably less than about 50 μm, 50% of the particles have a particle size (D50) of less than about 50 μm, preferably less than about 30 μm, and 10% of the particles have a particle size (D10) of less than about 30 μm, preferably less than about 10 μm.
[0081] In a fourth aspect of the fifth embodiment of the present invention, the micronized crystal form S of the elasilan hydrochloride of formula -1a produced by the present invention is characterized by its particle size distribution: wherein 90% of the particles have a particle size (D90) of less than about 15 μm, 50% of the particles have a particle size (D50) of less than about 10 μm, and 10% of the particles have a particle size (D10) of less than about 5 μm.
[0082] In the sixth embodiment of the present invention, the crystal form S obtained according to the present invention is used to expose the sample to different %RH conditions (for 1 hour at each %RH) using a DVS (Dynamic Vapor Adsorption) instrument, and PXRD patterns are collected at each %RH. This study is referred to herein as variable humidity powder X-ray diffraction (VH-PXRD) study.
[0083] In one aspect of the sixth embodiment, a superimposed diagram of the VH-PXRD spectra of crystal form S after 1 hour of exposure at different %RH is shown below. Figure 5 As shown.
[0084] In the seventh embodiment of the present invention, the micronized crystal form S obtained according to the present invention is taken, and the sample is exposed to different %RH conditions (for 1 hour at each %RH) using a DVS (Dynamic Vapor Adsorption) instrument, and PXRD spectra are collected at each %RH. This study is referred to herein as the VH-PXRD study.
[0085] In one aspect of the seventh embodiment, a superimposed diagram of the VH-PXRD spectra of the micronized crystal form S after 1 hour of exposure at different %RH conditions is shown below. Figure 7 As shown.
[0086] In the eighth embodiment of the present invention, crystal form S obtained according to the present invention is used to generate 0%RH in a desiccator under sealed conditions using P2O5, the sample is exposed to 0%RH for 2 hours, and PXRD is collected.
[0087] In one aspect of the eighth embodiment, the PXRD pattern of crystal form S after exposure to 0%RH for 2 hours is as follows: Figure 9 As shown.
[0088] In the ninth embodiment of the present invention, the micronized crystal form S obtained according to the present invention is taken, and 0%RH is generated in a desiccator using P2O5 under sealed conditions. The sample is exposed to 0%RH for 2 hours, and PXRD is collected.
[0089] In one aspect of the ninth embodiment, the PXRD pattern of the micronized crystal form S after exposure to 0%RH for 2 hours is as follows: Figure 10 As shown.
[0090] In the tenth embodiment of the present invention, the crystal form S obtained according to the present invention is taken, and the sample is exposed to different temperatures in the range of 25°C to 205°C, and PXRD patterns are acquired at each temperature. This study is referred to herein as variable temperature powder X-ray diffraction (VT-PXRD) study.
[0091] In one aspect of the tenth embodiment, a superimposed diagram of the VT-PXRD spectra of crystal form S after exposure at different temperatures ranging from 25°C to 205°C is shown below. Figure 6 As shown.
[0092] In the eleventh embodiment of the present invention, the micronized crystal form S obtained according to the present invention is taken and the sample is exposed to different temperatures in the range of 25°C to 205°C, and PXRD patterns are collected at each temperature. This study is referred to herein as variable temperature powder X-ray diffraction (VT-PXRD) study.
[0093] In one aspect of the eleventh embodiment, a superimposed image of the VT-PXRD patterns of the micronized crystal form S after exposure at different temperatures ranging from 25°C to 205°C is shown below. Figure 7 As shown.
[0094] The twelfth embodiment of the present invention provides a method for preparing crystal form 1B of the elasis group of formula -1a, comprising: a) Provide a solution of leprastran hydrochloride in a solvent. b) Crystal form 1B of the isolax hydrochloride group of the isolated form -1a; In step a), the solution of ellastan hydrochloride can be prepared by mixing ellastan hydrochloride with a solvent at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used, or the solution in step a) can be obtained by a synthetic process for preparing ellastan hydrochloride; the solvent is selected from propylene glycol, dimethyl sulfoxide (DMSO), etc.; in step b), the separation of ellastan hydrochloride crystal form 1B can be performed by mixing with an antisolvent and then filtering the compound; wherein the antisolvent is selected from hydrocarbon solvents, ether solvents, etc.
[0095] The thirteenth embodiment of the present invention provides a new crystal form of the allasu group of formula-1a, hereinafter referred to as crystal form N.
[0096] In a first aspect of the thirteenth embodiment, a crystal form N of the allasu group of formula-1a is provided, characterized in that its powder X-ray diffraction (PXRD) pattern has peaks at approximately 5.7°, 7.9°, 9.9° and 21.0° ± 0.2° 2θ.
[0097] In a second aspect of the thirteenth embodiment, a crystal form N of the allasu group of formula-1a is provided, characterized in that its powder X-ray diffraction (PXRD) pattern has peaks at approximately 5.7°, 7.9°, 9.9°, 12.1°, 13.0°, 14.4° and 21.0° ±0.2° 2θ.
[0098] In a third aspect of the thirteenth embodiment, a crystal form N of ellasyl hydrochloride is provided, characterized by its PXRD pattern as shown below. Figure 12 As shown.
[0099] The fourteenth embodiment of the present invention provides a method for preparing the crystal form N of the allergan hydrochloride group of formula -1a, comprising: a) Provide a solution of ellastatin in an ether solvent. b) Mix the solution with a hydrochloric acid source. c) Crystal form N of the isolax hydrochloride group of the isolated formula -1a; In step a), the solution is provided by dissolving ellastatin in an ether solvent at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used, or the solution in step a) can also be obtained by a synthetic process for preparing ellastatin; the hydrochloric acid source in step b) is selected from concentrated hydrochloric acid, hydrogen chloride gas, etc.; the separation of ellastatin hydrochloride crystal form N in step c) is achieved by removing the solvent using known techniques, which are selected from: mixing with an antisolvent; or cooling the mixture to a lower temperature and then filtering the mixture; or crystallization.
[0100] The fifteenth embodiment of the present invention provides lassyl succinate of formula-1b.
[0101]
[0102] In a first aspect of the fifteenth embodiment, the compound of formula -1b can be isolated in solid form.
[0103] In a second aspect of the fifteenth embodiment, the solid is obtained in the form of a crystalline solid, and the crystal form is named crystal form M.
[0104] In a third aspect of the fifteenth embodiment, the compound of formula -1b is characterized by its PXRD pattern as shown in the figure. Figure 13 As shown.
[0105] The sixteenth embodiment of the present invention provides a method for preparing lassyl succinate of formula -1b, comprising: a) Provide a solution of ellastatin and succinic acid in a solvent. b) Isolate lassyl succinate; In step a), the solution is provided by dissolving ellastatin in a solvent and adding succinic acid at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used; or dissolving ellastatin and succinic acid in a solvent at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used; or the solution in step a) can also be obtained by a synthetic process for preparing ellastatin, followed by the addition of succinic acid; the solvent is selected from alcohol solvents, such as isopropanol; the separation of ellastatin succinate in step b) can be performed by known techniques selected from: mixing with an antisolvent; or cooling the mixture to a lower temperature and then filtering the mixture; or crystallization.
[0106] In one aspect of the sixteenth embodiment, the succinate lassone of formula-1b is further used to prepare pure formula-1 lassone or a pharmaceutically acceptable salt thereof.
[0107] The seventeenth embodiment of the present invention provides ellaxis group of formula -1c fumarate.
[0108]
[0109] In a first aspect of the seventeenth embodiment, the compound of formula -1c is isolated in solid form.
[0110] In a second aspect of the seventeenth embodiment, the solid is obtained in the form of a crystalline solid, and the crystal form is named crystal form S.
[0111] In a third aspect of the seventeenth embodiment, the crystal form S of formula -1c is characterized by its PXRD pattern as follows: Figure 14 As shown.
[0112] The eighteenth embodiment of the present invention provides a method for preparing ellastrantrol fumarate of formula -1c, comprising: a) Provide a solution of ilexanthan and fumaric acid in a solvent. b) Isolate lassyl succinate; In step a), the solution is provided by dissolving ellastatin in a solvent and adding fumaric acid at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used; or dissolving ellastatin and succinic acid in a solvent at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used; or the solution in step a) can also be obtained by a synthetic process for preparing ellastatin, followed by the addition of fumaric acid; the solvent is selected from alcohol solvents, such as isopropanol; the separation of ellastatin fumarate in step b) can be performed by known techniques selected from: mixing with an antisolvent; or cooling the mixture to a lower temperature and then filtering the mixture; or crystallization.
[0113] In one aspect of the eighteenth embodiment, the ellaslan fumarate of formula -1c is further used to prepare pure ellaslan of formula -1 or a pharmaceutically acceptable salt thereof.
[0114] The allastrantran hydrochloride used as a raw material in this invention can be prepared by any method disclosed in the literature (such as US 7612114 B2), or by the method described in the literature or by common knowledge of those skilled in the art.
[0115] The crystal forms of ellastrone hydrochloride, ellastrone succinate and ellastrone fumarate obtained according to the present invention have a purity greater than about 99%, preferably greater than about 99.5%, more preferably greater than about 99.7%, and most preferably greater than about 99.8%, as determined by high performance liquid chromatography (HPLC).
[0116] The crystal forms of ellastrand hydrochloride, ellastrand succinate, and ellastrand fumarate can be further micronized or pulverized to obtain the desired particle size, thereby achieving the desired solubility properties, depending on the requirements of different pharmaceutical compositions. Techniques for reducing particle size include, but are not limited to, single-stage or multi-stage micronization using cutting mills, pin / cage mills, hammer mills, air jet mills, fluidized bed air jet mills, ball mills, and roller mills. Pulverization or micronization can be performed before or after product drying.
[0117] In the nineteenth embodiment of the present invention, the crystal forms obtained according to the present invention (such as crystal forms M, S and N of the ellasyl hydrochloride group of formula-1a) are used to prepare various pharmaceutical preparations.
[0118] The twentieth embodiment of the present invention provides a pharmaceutical composition comprising a crystal form obtained according to the present invention (such as crystal form M, crystal form S and crystal form N of ellastrone hydrochloride of formula -1a) and at least one pharmaceutically acceptable excipient.
[0119] In the twenty-first embodiment of the present invention, allastatin succinate and allastatin fumarate are used to prepare various pharmaceutical formulations.
[0120] The twenty-second embodiment of the present invention provides a pharmaceutical composition comprising elasilane hydrochloride, elasilane succinate and elasilane fumarate crystal forms obtained according to the present invention, and at least one pharmaceutically acceptable excipient.
[0121] The terms "pharmaceutical composition" or "pharmaceutical preparation" as used herein include tablets, pills, powders, liquids, suspensions, emulsions, granules, capsules, suppositories, or injectable preparations.
[0122] Suitable pharmaceutically acceptable excipients are selected from, but are not limited to, binders, diluents, disintegrants, surfactants, and lubricants. Suitable binders include: polyvinylpyrrolidone, copovidone, starch (such as pregelatinized starch), cellulose derivatives (such as hydroxypropyl methylcellulose, ethylcellulose, hydroxypropyl cellulose, and carboxymethyl cellulose), gelatin, gum arabic, agar, alginate, carbomer, chitosan, glucose binders, cyclodextrin, dextrin, glyceryl disorbate, guar gum, hydroxypropyl methylcellulose, maltodextrin, poloxamer, polycarboxylic acid, polydextrose, polyethylene oxide, polymethacrylate, sodium alginate, sucrose, or mixtures thereof; suitable diluents include: anhydrous lactose, lactose monohydrate, modified lactose, dibasic calcium phosphate, tribasic calcium phosphate, and microcrystalline fibers. Suitable disintegrants include: silicified microcrystalline cellulose, powdered cellulose, corn starch, pregelatinized starch, calcium carbonate, sucrose, glucose, glucose binders, dextrin, dextrose, fructose, lactitol, mannitol, sorbitol, starch, calcium lactate, or mixtures thereof; suitable disintegrants include: magnesium aluminum silicate (or magnesium aluminum silicate), starch, pregelatinized starch, sodium carboxymethyl starch, crospovidone, crospovidone carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, alginate, sodium carboxymethyl cellulose, sodium alginate, calcium alginate, and chitosan; suitable lubricants include (but are not limited to): magnesium stearate, stearic acid, palmitic acid, talc, and fumed silica (Aerosil). Suitable surfactants that may be used include (but are not limited to): polysorbate 80, polyoxyethylene sorbitol, polyoxyethylene-polyoxypropylene copolymer, and sodium dodecyl sulfate; β-cyclodextrins include (but are not limited to): sulfobutyl alkyl ether-β-cyclodextrin, sulfobutyl ether-β-cyclodextrin sodium, or hydroxypropyl-β-cyclodextrin.
[0123] One embodiment of the present invention discloses a method for treating a patient in need. The method includes administering a therapeutically effective amount of a crystalline form of ellastrantran hydrochloride, ellastrantran succinate, or ellastrantran fumarate obtained according to the present invention. The crystalline form is intended for treating postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutant advanced or metastatic breast cancer who have experienced disease progression following at least one line of endocrine therapy.
[0124] P-XRD analysis method: PXRD analysis of the compound of formula -1a of this invention was performed using a BRUKER / D8 ADVANCE diffractometer with Cu Kα radiation at a wavelength of 1.5406 Å.
[0125] VH-PXRD analysis method: PXRD analysis of the compound of formula -1a was performed using a Bruker D8 diffractometer with Cu Kα radiation (40 kV, 30 mA), an θ-2θ goniometer, a V4 diverging and receiving slit, a Ge monochromator, and a Lynxeye XE (1D mode) detector. The instrument's performance was checked using certified corundum standards (NIST 1976). Data acquisition was performed using Diffrac Plus XRD Commander v2.6.1, and data analysis and presentation were performed using Diffrac Plus EVA v15.0.0.0.
[0126] Samples were exposed to different humidity conditions ranging from 10%RH to 95%RH for 1–2 hours using a DVS (Dynamic Vapor Adsorption) instrument, and PXRD spectra were acquired. PXRD data were acquired at 298.15 K and a water temperature of 35.0°C, with an angle range of 2–49°, a step size of 0.03°, a acquisition time of 28.6 seconds per step, and an acquisition time of 6 minutes and 29 seconds per %RH.
[0127] VT-PXRD sample analysis method parameters: PXRD analysis of the compound of formula -1a was performed using a PANalytical Empyrean diffractometer with CuKα radiation (45 kV, 40 mA), an θ-2θ goniometer, a V4 diverging and receiving slit, a Ge monochromator, and a PIXcel detector. The instrument's performance was checked using a certified corundum standard (NIST 1976). Data acquisition was performed using Xpert software, and data analysis and presentation were performed using Diffrac Plus EVA v15.0.0.0.
[0128] Samples tested under non-environmental conditions were fixed to silicon wafers using a thermally conductive compound. The samples were then heated from ambient temperature to the desired temperature at a rate of 20°C / min, followed by isothermal holding for 1 minute before data acquisition began. PXRD data were acquired from 5° to 39.9° in 0.013° increments, with each acquisition step lasting 18.8 seconds, and an acquisition time of 3 minutes and 37 seconds per %RH level.
[0129] The best mode for carrying out the present invention is illustrated by the following examples. These examples are for illustrative purposes only and should not be considered as limiting the scope of the invention.
[0130] Example Example 1: Preparation of crystal form M of ellasyl hydrochloride of formula 1a
[0131] Allassamyl hydrochloride (1 g) was dissolved in N,N-dimethylformamide (30 ml) at 60-65°C. The resulting solution was cooled to 25-30°C, and methyl tert-butyl ether (90 ml) was added to the solution, while stirring at the same temperature. The solid was filtered off, washed with methyl tert-butyl ether, and dried to obtain the target compound.
[0132] Yield: 0.96 g. The PXRD pattern of the obtained compound is shown below. Figure 1 As shown.
[0133] Example 2: Preparation of crystal form S of ellasyl hydrochloride of formula 1a Dissolve 1 g of ellastatin hydrochloride in a mixture of acetone (20 ml) and water (40 ml) at 25–30°C. Filter the resulting solution. Completely evaporate the solvent from the filtrate and dry to obtain the target compound.
[0134] Yield: 0.85 g. The PXRD pattern of the obtained compound is shown below. Figure 2 As shown.
[0135] Example 3: Preparation of crystal form S of ellasyl hydrochloride of formula 1a Dissolve 5 g of ellagic acid hydrochloride in a mixture of acetone (50 ml) and water (10 ml) at 45–55°C. Slowly cool the solution to 0–5°C while stirring at the same temperature. Add acetone to the mixture at 0–5°C, raise the temperature of the mixture to 25–30°C, and stir at the same temperature. Filter off the solid, wash with acetone, and dry to obtain the target compound.
[0136] Yield: 4.5 g. The PXRD pattern of the obtained compound is shown below. Figure 3 As shown.
[0137] Example 4: Micronization of crystal form S of elastosyl hydrochloride of formula 1a The crystalline form S of lelastan hydrochloride was micronized using a micronizer. 25 g of crystalline form S of lelastan hydrochloride was added to the micronizer. Micronization was initiated by slowly feeding the material through the product feed funnel into the micronizer hopper at a feed rate of 3 to 4 kg / h, with pulverizing pressure applied. Finally, the collector was removed from the micronizer, and the material was discharged, yielding the micronized crystalline form S.
[0138] Yield: 21.3 g. The PXRD pattern of the obtained compound is shown below. Figure 4 As shown.
[0139] Example 5: Preparation of crystal form 1B of elastosyl hydrochloride of formula 1a Allasylhydrochloride (1 g) was dissolved in dimethyl sulfoxide (10 ml) at 75-80°C. Toluene (50 ml) was added to the above solution, and the mixture was stirred at the same temperature. The mixture was cooled to 25-30°C and stirred at the same temperature. The solid was filtered off, washed with toluene, and dried to obtain the target compound.
[0140] Yield: 0.87 g. The PXRD pattern of the obtained compound is shown below. Figure 11 As shown.
[0141] Example 6: Preparation of crystal form 1B of elastosyl hydrochloride of formula 1a Allassamyl hydrochloride (0.5 g) was dissolved in propylene glycol (5 ml) at 25–30°C. Methyl tert-butyl ether (15 ml) was added to the solution at 25–30°C, and the mixture was stirred at the same temperature. The solid was filtered off, washed with methyl tert-butyl ether, and dried to obtain the target compound.
[0142] Yield: 0.36 g. The PXRD pattern of the obtained compound is shown below. Figure 11 As shown.
[0143] Example 7: Preparation of Irastrant Ilazoline hydrochloride (2 g) was dissolved in water (30 ml) at 45-50°C, and the resulting solution was cooled to 25-30°C. An aqueous solution of sodium bicarbonate was added to the solution, and the mixture was stirred at the same temperature. The solid was filtered off, washed with water, and a wet solid was obtained. The wet solid was slurried in water, filtered off, washed with water, and dried to obtain the target compound. Yield: 1.5 g.
[0144] Example 8: Preparation of the N-type crystal of the allergic hydrochloride group of formula 1a Irasil (1.4 g) was dissolved in tetrahydrofuran (THF) (28 ml) at 60–65°C. Hydrochloric acid (0.57 ml) was added to the solution at 60–65°C, and the mixture was stirred at the same temperature. The mixture was cooled to 25–30°C and stirred at the same temperature. The solid was filtered off, washed with tetrahydrofuran, and dried to give the target compound.
[0145] Yield: 1.5 g. The PXRD pattern of the obtained compound is shown below. Figure 12 As shown.
[0146] Example 9: Preparation of crystal form M of succinate lassyl group Ilazoline (0.3 g) was dissolved in isopropanol (10 ml) at 60-65°C. Succinic acid (0.154 g) was added to the solution at 60-65°C, and the mixture was stirred at the same temperature. The resulting solution was cooled to 25-30°C and stirred at the same temperature. The solid was filtered off, washed with isopropanol, and dried to give the target compound.
[0147] Yield: 0.210 g. The PXRD pattern of the obtained compound is shown below. Figure 13 As shown.
[0148] Example 10: Preparation of crystal form S of ellastatin fumarate Ilazoline (0.3 g) was dissolved in isopropanol (10 ml) at 60-65°C. Fumaric acid (0.151 g) was added to the solution at 60-65°C, and the mixture was stirred at the same temperature. The resulting mixture was cooled to 25-30°C and stirred at the same temperature. The solid was filtered off, washed with isopropanol, and dried to give the target compound.
[0149] Yield: 0.250 g. The PXRD pattern of the obtained compound is shown below. Figure 14 As shown.
Claims
1. A crystal form S of the allergic hydrochloride group represented by formula -1a, Its features are, Its powder X-ray diffraction (PXRD) peaks are located at approximately 7.9°, 9.6°, and 11.9° ± 0.2° 2θ.
2. The crystal form S of the allasu group according to claim 1, further characterized in that its powder X-ray diffraction (PXRD) peaks are located at approximately 3.0°, 6.1° and 24.1° ± 0.2° 2θ.
3. The crystal form S of the allasu group according to claim 1 is further characterized in that its powder X-ray diffraction (PXRD) pattern is essentially as shown in Figure 2.
4. The crystal form S of the allasu group according to claim 1 is further characterized in that its powder X-ray diffraction (PXRD) pattern is substantially as shown in Figures 3 and 4.
5. A crystal form S of ellasyl hydrochloride, characterized in that, Its powder X-ray diffraction (PXRD) peaks are located at approximately 3.0°, 6.1°, 7.9°, 9.6°, 11.9° and 24.1° ± 0.2° 2θ.
6. A method for preparing crystal form S of the allergic hydrochloride group shown in formula -1a, include: a) Dissolve or suspend leprastan hydrochloride in a solvent. b) Crystal form S of the isolax hydrochloride group of the isolated form -1a.
7. The method according to claim 6, wherein the dissolution or suspension of ellastatin hydrochloride in step a) can be carried out by mixing the ellastatin hydrochloride in a solvent at a suitable temperature in the range of about 0°C to the reflux temperature of the solvent, or it can be obtained by a synthetic process for preparing ellastatin hydrochloride.
8. The method of claim 7, wherein the solvent is selected from ketone solvents, alcohol solvents, ester solvents, ethyl formate, water and / or mixtures thereof.
9. The method according to claim 8, wherein the solvent is a mixture of a ketone solvent and water.
10. The method according to claim 9, wherein the ketone solvent is acetone.
11. The method of claim 6, wherein the separation of the crystalline form S of the ellasyl hydrochloride in step b) can be performed by removing the solvent using suitable techniques, including but not limited to decantation, evaporation, flash evaporation, concentration of mixtures, stirred film drying (ATFD), melt extrusion, spray drying, freeze drying (lyophilization), spray freeze drying, cooling the mixture or solution to a lower temperature followed by filtration, film drying, and mixing with an antisolvent.
12. The method of claim 11, wherein the separation of the crystal form S is carried out by evaporation and concentration of the mixture.
13. The method of claim 11, wherein the separation of the crystal form S is performed by mixing with an antisolvent and then filtering the compound; wherein the antisolvent is selected from ketone solvents and ester solvents.
14. The method of claim 13, wherein the antisolvent is acetone.
15. An alastan hydrochloride, characterized in that... The particle size distribution shows that D90 is less than approximately 100 μm.
16. The allaspirin hydrochloride of claim 15, wherein the allaspirin hydrochloride is in crystal form S.
17. A micronized ellastatin hydrochloride, characterized in that... The particle size distribution shows that D90 is less than approximately 15 μm.
18. The micronized lasalosyl hydrochloride according to claim 17, wherein the lasalosyl hydrochloride is in crystal form S.
19. A method for preparing crystal form M of the allergic hydrochloride group shown in formula -1a, include: a) Provide a solution of ellastatin hydrochloride in N,N-dimethylformamide (DMF). b) Crystal form M of the isolax hydrochloride group of the isolated form -1a.
20. The method of claim 19, wherein the solution in step a) is obtained by dissolving ellastatin hydrochloride in N,N-dimethylformamide at a temperature ranging from about 25°C to the reflux temperature of the solvent used, or the solution in step a) is also obtained by a synthetic process for preparing ellastatin hydrochloride.
21. The method of claim 19, wherein the separation of the crystal form M of ellasyl hydrochloride in step b) can be performed by mixing with an antisolvent and then filtering the compound; wherein the antisolvent is methyl tert-butyl ether.
22. A method for preparing the crystalline form N of the elasis hydrochloride group of formula -1a, comprising: a) Provide a solution of ellastatin in an ether solvent. b) Mix the solution with a hydrochloric acid source. c) Crystal form N of the isolax hydrochloride group of the isolated form -1a.
23. The method of claim 22, wherein the solution provided in step a) is provided by dissolving ellastatin in an ether solvent at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used, or the solution in step a) is also obtained by a synthetic process for preparing ellastatin; the hydrochloric acid source in step b) is selected from concentrated hydrochloric acid, hydrogen chloride gas; and the separation of ellastatin hydrochloride crystal form N in step c) is performed by removing the solvent using known techniques selected from: mixing with an antisolvent; or cooling the mixture to a lower temperature and then filtering the mixture; or crystallization.
24. The succinate lassyl group shown in Formula-1b.
25. The succinate group according to claim 24, wherein the compound of formula -1b is isolated in solid form.
26. The succinate group according to claim 25, wherein the solid is obtained in the form of a crystalline solid, and the crystal form is named crystal form M.
27. The succinate elasis group according to claim 26, wherein the crystal form M of formula -1b is characterized by its powder X-ray diffraction (PXRD) pattern as shown in Figure 13.
28. A method for preparing lassyl succinate of formula -1b, comprising: a) Provide a solution of ellastatin and succinic acid in a solvent. b) Isolation of lassyl succinate.
29. The method of claim 28, wherein the solution provided in step a) is provided by dissolving ellastatin in a solvent and adding succinic acid at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used; or dissolving ellastatin and succinic acid in a solvent at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used; or the solution in step a) may also be obtained by a synthetic process for preparing ellastatin, followed by the addition of succinic acid; wherein the solvent is selected from alcohol solvents, such as isopropanol; and wherein the separation of ellastatin succinate in step b) is performed by known techniques selected from: mixing with an antisolvent; or cooling the mixture to a lower temperature and then filtering the mixture; or crystallization.
30. The method of claim 28, wherein the succinate lassyl group of formula-1b is further used to prepare pure formula-1 lassyl group or a pharmaceutically acceptable salt thereof.
31. The ellaxis group of fumarate shown in Formula-1c.
32. The ellasyl fumarate group according to claim 31, wherein the compound of formula -1c is isolated in solid form.
33. The ellasyl fumarate group according to claim 32, wherein the solid is obtained in the form of a crystalline solid, and the crystal form is named crystal form S.
34. The elasis group of fumarate according to claim 33, wherein the crystal form S of formula -1c is characterized by its powder X-ray diffraction (PXRD) pattern as shown in Figure 14.
35. A method for preparing ellastrantran fumarate of formula -1c, comprising: a) Provide a solution of ellastatin and fumaric acid in a solvent. b) Isolation of lassyl succinate.
36. The method of claim 35, wherein providing the solution in step a) can be performed by dissolving ellastatin in a solvent and adding fumaric acid at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used; or dissolving ellastatin and succinic acid in a solvent at a suitable temperature within the range of about 25°C to the reflux temperature of the solvent used; or the solution in step a) can also be obtained by a synthetic process for preparing ellastatin, followed by the addition of fumaric acid; the solvent is selected from alcohol solvents, such as isopropanol; the separation of ellastatin fumarate in step b) can be performed by mixing with an antisolvent, or by cooling the mixture to a lower temperature and then filtering the mixture or crystallizing.
37. The method of claim 35, wherein the ellaslan fumarate of formula -1c is further used to prepare pure ellaslan of formula -1 or a pharmaceutically acceptable salt thereof.
38. Use of the crystal forms M and N of the allastatin hydrochloride of formula -1a obtained according to the preceding claims in the preparation of various pharmaceutical formulations.
39. The use of the crystal form S of ellasyl hydrochloride of formula -1a obtained according to the preceding claims in the preparation of various pharmaceutical formulations.
40. A pharmaceutical composition comprising one or more crystal forms of ellastridium hydrochloride of formula -1a according to the preceding claim, selected from crystal form M and crystal form N, and at least one pharmaceutically acceptable excipient.
41. A pharmaceutical composition comprising crystal form S of ellastatin hydrochloride of formula -1a according to the preceding claim, and at least one pharmaceutically acceptable excipient.
42. The use of crystalline forms M and N of ellastridium hydrochloride of formula 1a, and one or more pharmaceutically acceptable excipients, in the preparation of pharmaceutical formulations.
43. The use of the crystal form S of ellastridium hydrochloride of formula 1a and one or more pharmaceutically acceptable excipients for the preparation of pharmaceutical formulations.
44. A method of treating a patient in need, comprising administering to the patient a therapeutically effective amount of elasilan hydrochloride in crystal form M and crystal form N of formula-1a, and one or more pharmaceutically acceptable excipients.
45. A method of treating a patient in need, comprising administering to the patient a therapeutically effective amount of crystal form S of ellastrant hydrochloride of formula-1a and one or more pharmaceutically acceptable excipients.
Citation Information
Patent Citations
Polymorphic forms of RAD1901-2HCL
US10385008B2
Polymorphic forms of RAD1901-2HCl
US11643385B2
Selective estrogen receptor modulator
US7612114B2
Processes and intermediates for the preparation of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-YL)-1h-pyrazole-4-carboxamide
WO2022056100A1
Crystal form of elacestrant dihydrochloride, preparation method therefor, and use thereof
WO2023227029A1
